Here's a Protocol. Here's Everything Wrong With It.
How to Read a Peptide Protocol: A Complete Checklist
Eight articles of tools, applied. We take an ordinary peptide protocol and dismantle it line by line — then hand you the checklist to do it yourself.
Eight articles ago you might have read this and saw nothing unusual:
12-Week Recomp Stack
CJC-1295 100mcg + Ipamorelin 200mcg — 5×/week before bed BPC-157 250mcg daily TB-500 2mg twice weekly
Run 12 weeks. Four weeks off. Repeat.
It looks like a plan. It has compounds, amounts, timings, a duration, and a break. It's more specific than most of what circulates.
By the end of this article you'll have found somewhere between twelve and fifteen serious problems with it — and you'll have found most of them before I point them out.
That's the whole purpose of the series.
The eight tools
Quickly, because you already have these:
1. A name isn't a molecule. Which version? 2. Small structural changes aren't small changes. 3. These are injected for a chemical reason, not a commercial one. 4. Forty amino acids governs the entire regulatory landscape. 5. Real engineering closes every clearance route and pays for it somewhere. 6. A fragment inherits an assumption, not an activity. 7. Some compounds have a ceiling, and past it only side effects scale. 8. "No interactions" is half a sentence.
Now the missing piece: what a protocol is actually supposed to contain.
What a real protocol looks like
The word "protocol" is doing a lot of unearned work in this space. In clinical practice and in research it means a specific document with a defined structure — and comparing that structure to what circulates online is instructive on its own.
Notice what dominates that list. Only one section concerns what you take. Everything else concerns whether it's appropriate, whether it's working, whether it's causing harm, and what you do about any of that.
A dosing schedule isn't a protocol. It's one field of one section.
The checklist
Five categories. Every question maps to something the series has covered.
Twenty-two questions. Most protocols circulating online answer two or three.
The demolition
Now the example, line by line. I'll flag which article covers each failure so you can see the tools working.
CJC-1295 100mcg
No DAC status. This is the single most consequential omission in the document. Two molecules share this name and their durations differ by roughly three hundred-fold (Article 1). Without knowing which one, nothing else about this line can be evaluated.
And the omission interacts with the schedule. Five times weekly is a plausible frequency for a thirty-minute molecule. Applied to the version that persists for a week, it produces continuous accumulation — sustained, uninterrupted exposure to a system that operates in bursts (Article 7). For what it's worth, human studies of the long-acting form found that GH secretion remained pulsatile despite sustained IGF-1 elevation, so continuous exposure doesn't simply flatline the rhythm. But accumulation is still accumulation, and without knowing which molecule is in the vial, there's no way to assess the exposure pattern at all.
No identity information at all. No sequence, no molecular weight, no salt form. A stated weight in micrograms is ambiguous when the material may be a salt — a milligram of salt is not a milligram of peptide (Article 1).
Not approved anywhere. Not stated. Development was discontinued; there is no established human dose. So the "100mcg" has no derivation. It comes from convention, and convention here means other documents like this one.
+ Ipamorelin 200mcg
Ceiling not addressed. This is a secretagogue — it asks the pituitary to release its own supply. Three separate mechanisms limit how much that request can achieve: a finite store, negative feedback, and receptor desensitization (Article 7). Nothing in this protocol acknowledges any of them, or states what would indicate the ceiling had been reached.
Twelve continuous weeks. Sustained stimulation of this receptor family reduces responsiveness over time. The protocol runs straight through with no variation. The four-week break at the end may or may not be sufficient — the document doesn't say what it's for, so there's no way to assess it.
Stacking rationale absent. Two compounds acting on the same axis by different routes. There are arguments for that. The protocol makes none of them, and gives no way to attribute an effect — or an adverse effect — to either compound.
BPC-157 250mcg daily
Fragment assumption, unstated. The claim rests on a sequence derived from a larger protein retaining that protein's activity. That's an assumption, not a finding, and it needs demonstrating rather than asserting (Article 6).
Human evidence not characterized. The protocol doesn't state what's known. It should — and the honest version of that statement is short.
A name that asserts its own conclusion. The abbreviation stands for a phrase describing what the compound supposedly does (Article 2). That's a claim wearing an identifier's clothing.
Regulatory status omitted — and it's moving. The FDA previously acted to remove BPC-157 from compounding eligibility under 503A. Then, in July 2026, the FDA's own Pharmacy Compounding Advisory Committee voted to recommend adding it back to the 503A bulk-substance list — a non-binding recommendation that is not final FDA action. Neither "it's banned" nor "the FDA approved it" is accurate right now, and any protocol that doesn't mention the regulatory uncertainty is leaving out a material fact (Article 4).
TB-500 2mg twice weekly
Which molecule? This name refers sometimes to a 43-amino-acid protein and sometimes to a seven-amino-acid piece of it (Article 1). Those aren't variants. They're different compounds — and one sits above the forty-residue line and one below it, which means they're in different regulatory categories as well (Article 4).
The same fragment assumption, in a second compound (Article 6).
A dose eight times larger than anything else here, with no explanation of why. Dose magnitude isn't arbitrary; it follows from potency and exposure. Nothing here derives it.
The document as a whole
No indication. "Recomp" isn't a clinical problem, a diagnosis, or a measurable endpoint. Without a defined problem there's no way to determine whether the intervention is appropriate or whether it worked.
No baseline. Nothing measured before starting. So nothing can be compared afterward — any perceived change is uncontrolled and unattributable.
No monitoring. Nothing measured during. Growth-hormone-axis compounds affect glucose handling (Article 8); nothing here checks.
No stop criteria. This is the most dangerous omission in the entire document. There is no stated circumstance under which you would discontinue — no symptom, no value, no threshold. A protocol without stop criteria cannot fail. It can only continue.
No interaction consideration. No mention of other medications, and no mention of disclosure to any clinician (Article 8).
No storage or handling. These are peptides in solution after reconstitution, with real stability constraints. Nothing here addresses preparation, storage, or how long a reconstituted vial remains usable.
No exit. "Repeat" is not an exit strategy. There's no defined end and no criteria for stopping permanently.
No sourcing standard. Nothing about where the material comes from or how identity would be verified.
Somewhere between fifteen and twenty distinct failures, depending on how you count. Every one of them findable with the checklist.
⚠️ THE FIVE MOST COMMON FAILURES, RANKED BY HARM
1. No stop criteria. Nothing defines when to discontinue, so nothing triggers it. Whatever goes wrong, goes wrong for the full duration.
2. Ambiguous identity. Where a name maps to multiple molecules, every downstream decision is unfounded.
3. No monitoring. Changes that would be caught by a routine measurement aren't caught at all.
4. Undisclosed use. The clinician who could manage a problem doesn't know there's anything to manage.
5. No defined endpoint. Without a stated goal, there's no way to conclude the intervention succeeded, failed, or should stop.
Note that four of the five concern safety architecture rather than the compounds themselves. That's the pattern: bad protocols aren't usually wrong about pharmacology. They're silent about everything except dosing.
What good looks like
For contrast, look at the labelling of any approved peptide drug — teriparatide, octreotide, semaglutide. These documents are public and free.
You'll find every one of the twelve sections above. Specific indication. Explicit exclusions. Required baseline assessment. A dose derived from trials, with the trials named. Escalation rules with decision points. Monitoring schedules. Adverse events by frequency, with management. Interaction lists. Defined treatment duration.
Read one. It takes twenty minutes and it recalibrates permanently what the word "protocol" should mean. Nothing else in this series will do more for your judgement in less time.
The honest limits
Some clarity about what these nine articles have and haven't given you.
You can now evaluate. You can read a protocol, a product page, or a claim and identify what's missing, what's assumed, and what's asserted without support. That's a real skill and most people in this space don't have it.
You cannot now prescribe. Writing a protocol for another person is a licensed medical act nearly everywhere, and for good reason — it requires knowing the individual's history, medications, and risk factors, and carrying responsibility for the outcome. Nothing here confers any of that.
And evaluating a protocol isn't the same as validating one. A protocol that survives every question on the checklist has cleared a structural bar. It could still be built on a compound with no human evidence behind it. The checklist finds what's absent. It can't manufacture evidence that was never generated.
The realistic use of what you have: better questions. Of a supplier, of a source, of a clinician, and of your own reasoning.
Where this goes
The method here isn't specific to peptides.
Ask what a thing actually is. Ask where the number came from. Ask what's demonstrated versus inherited. Ask what would have to be true for the claim to hold, and whether anyone checked. Ask what's missing rather than only evaluating what's present.
That transfers to supplements, to devices, to diagnostics, to most health claims you'll encounter. The peptide space is a useful training ground mainly because the gaps are so wide and so consistent.
You started this series being told what to think about these compounds by people selling them.
You finish it able to work it out.
📄 Download the complete checklist — the twenty questions, formatted for reference.
← Start the series from the beginning: The Same Name, Two Different Drugs
View all nine articles → The Peptide Literacy Series
This article is educational and not medical advice. The protocol example is constructed for illustration and is not reproduced from any source. It does not recommend any compound, dose, or protocol. Decisions about any therapy belong with a qualified clinician who knows your history.